— A modelling study released in March gives a clue at which price the six-monthly anti-HIV jab, lenacapavir, would be worth the health department’s while.
— The health department needs to step in, as the US government is unlikely to stick to a December commitment to buy the medicine for countries like South Africa, along with the Global Fund for HIV, TB and Malaria.
— Lenacapavir works by stopping HIV from making more copies of itself and so getting into someone’s immune cells and is 100% effective for teen girls and young women.
— The study shows if the shot is sold to South Africa at between R2 238–R4 304 per person per year — about 3.5 to 6.8 times what the health department pays for a daily anti-HIV pill — it would be as cost-effective as giving the pill to one to three million new people per year.
— The analysis shows the medication could slash new infections in South Africa between 27–41% ending AIDS by 2032 — but only if between two and four million HIV-negative people in the country use the jab every year over the next eight years.
Read the full analysis at Bhekisisa.
Source : Bhekisisa
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.